TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.
| Revenue (Most Recent Fiscal Year) | $616.29M |
| Net Income (Most Recent Fiscal Year) | $447.18M |
| PE Ratio (Current Year Earnings Estimate) | 24.13 |
| PE Ratio (Trailing 12 Months) | 12.12 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.70 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.98 |
| Pre-Tax Margin (Trailing 12 Months) | 17.42% |
| Net Margin (Trailing 12 Months) | 72.56% |
| Return on Equity (Trailing 12 Months) | 101.12% |
| Return on Assets (Trailing 12 Months) | 51.88% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.38 |
| Inventory Turnover (Trailing 12 Months) | 0.69 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $2.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 159.69M |
| Free Float | 142.70M |
| Market Capitalization | $5.36B |
| Average Volume (Last 20 Days) | 2.27M |
| Beta (Past 60 Months) | 1.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.64% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.58% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |